Highlights Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
7.890 ^USD	-0.25%		-11.45%	-10.54%

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT

Highlights

03-03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI
03-03	Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years	RE
03-03	Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag	MT
02-27	European Medicines Agency Panel Issues Negative Opinion on Vanda's Schizophrenia Treatment	MT
02-25	Vanda Pharmaceuticals Announces Fda Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	CI
02-25	Vanda Pharmaceuticals announces FDA acceptance of Biologics License Application filing for Imsidolimab for the treatment of generalized pustular psoriasis	RE
02-23	Top Premarket Gainers	MT
02-20	US FDA approves Vanda's antipsychotic pill, shares climb	RE
02-20	US FDA approves Vanda's psychiatric drug	RE
02-20	Vanda Pharmaceuticals Announces FDA Approval of BYSANTI (milsaperidone) for the Treatment of Bipolar I Disorder and Schizophrenia	CI
02-11	Vanda Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2026	CI
02-11	Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-08	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ®? Supplemental New Drug Application for Jet Lag Disorder	CI
01-08	Top Premarket Decliners	MT
12-31	Wall Street ends year's final session lower but ends 2025 with big annual gains	RE
12-31	Top Midday Gainers	MT
12-31	Vanda Pharmaceuticals Says FDA Has Approved Nereus for Motion-Induced Vomiting; Shares Rise Pre-Bell	MT
12-31	Vanda Pharmaceuticals Announces FDA Approval of Nereus? (tradipitant) for the Prevention of Vomiting Induced by Motion	CI
12-26	Top Premarket Gainers	MT
12-15	Vanda Pharmaceuticals Inc. Announces Submission of Biologics License Application to FDA for Imsidolimab for Treatment of Generalized Pustular Psoriasis	CI
12-15	Vanda Pharmaceuticals Submits Biologics License Application to US FDA for Generalized Pustular Psoriasis Drug	MT
12-15	Vanda announces submission of biologics license application to the FDA for Imsidolimab for the treatment of generalized pustular psoriasis	RE
12-04	Vanda Pharmaceuticals Inc. Announces that FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	CI
11-28	Vanda Pharmaceuticals Inc. Provides Regulatory Update on Tradipitant for Motion Sickness	CI
11-18	Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting	CI